Equities research analysts forecast that Catabasis Pharmaceuticals Inc (NASDAQ:CATB) will report earnings of ($0.27) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Catabasis Pharmaceuticals’ earnings, with estimates ranging from ($0.30) to ($0.23). Catabasis Pharmaceuticals reported earnings of ($0.32) per share in the same quarter last year, which suggests a positive year over year growth rate of 15.6%. The business is scheduled to announce its next earnings results on Thursday, August 9th.
According to Zacks, analysts expect that Catabasis Pharmaceuticals will report full year earnings of ($1.04) per share for the current fiscal year, with EPS estimates ranging from ($1.22) to ($0.86). For the next financial year, analysts forecast that the business will report earnings of ($1.56) per share, with EPS estimates ranging from ($1.90) to ($1.22). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Catabasis Pharmaceuticals.
Catabasis Pharmaceuticals (NASDAQ:CATB) last issued its earnings results on Thursday, May 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.06).
A number of research analysts have recently commented on CATB shares. Zacks Investment Research raised Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Tuesday, March 20th. ValuEngine raised Catabasis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. Finally, Wedbush raised their price target on Catabasis Pharmaceuticals from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Tuesday, March 20th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $5.18.
Shares of Catabasis Pharmaceuticals opened at $1.73 on Thursday, according to MarketBeat Ratings. The firm has a market capitalization of $48.78 million, a price-to-earnings ratio of -1.37 and a beta of 0.70. Catabasis Pharmaceuticals has a 1-year low of $1.09 and a 1-year high of $3.78.
Institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Catabasis Pharmaceuticals by 146.1% during the fourth quarter. Geode Capital Management LLC now owns 76,612 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 45,476 shares during the period. Deutsche Bank AG acquired a new position in shares of Catabasis Pharmaceuticals during the fourth quarter valued at $335,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Catabasis Pharmaceuticals by 167.2% during the fourth quarter. Renaissance Technologies LLC now owns 468,700 shares of the biotechnology company’s stock valued at $698,000 after purchasing an additional 293,300 shares during the period. 26.81% of the stock is currently owned by institutional investors.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases.
Get a free copy of the Zacks research report on Catabasis Pharmaceuticals (CATB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.